Oppenheimer & Co. Inc. Takes $309,000 Position in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)

Oppenheimer & Co. Inc. acquired a new stake in shares of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) during the second quarter, Holdings Channel reports. The institutional investor acquired 50,000 shares of the biotechnology company’s stock, valued at approximately $309,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Creative Planning grew its holdings in shares of Progenics Pharmaceuticals by 11.2% during the second quarter. Creative Planning now owns 19,900 shares of the biotechnology company’s stock valued at $123,000 after buying an additional 2,000 shares during the last quarter. Texas Permanent School Fund grew its holdings in shares of Progenics Pharmaceuticals by 3.8% during the first quarter. Texas Permanent School Fund now owns 57,403 shares of the biotechnology company’s stock valued at $266,000 after buying an additional 2,079 shares during the last quarter. Comerica Bank grew its holdings in shares of Progenics Pharmaceuticals by 4.4% during the first quarter. Comerica Bank now owns 83,763 shares of the biotechnology company’s stock valued at $422,000 after buying an additional 3,547 shares during the last quarter. Aperio Group LLC grew its holdings in shares of Progenics Pharmaceuticals by 14.9% during the second quarter. Aperio Group LLC now owns 33,843 shares of the biotechnology company’s stock valued at $209,000 after buying an additional 4,378 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale grew its holdings in shares of Progenics Pharmaceuticals by 23.3% during the first quarter. DekaBank Deutsche Girozentrale now owns 26,500 shares of the biotechnology company’s stock valued at $208,000 after buying an additional 5,000 shares during the last quarter. 77.97% of the stock is currently owned by hedge funds and other institutional investors.

A number of equities research analysts have recently weighed in on PGNX shares. UBS Group reissued a “positive” rating on shares of Progenics Pharmaceuticals in a report on Thursday, June 20th. BidaskClub raised shares of Progenics Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, August 23rd. Brookline Capital Management began coverage on shares of Progenics Pharmaceuticals in a report on Monday, July 29th. They issued a “buy” rating and a $10.00 price target on the stock. Zacks Investment Research raised shares of Progenics Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, May 22nd. Finally, ValuEngine raised shares of Progenics Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $9.55.

In other news, insider Lte Partners, Llc acquired 43,520 shares of the firm’s stock in a transaction on Thursday, September 5th. The stock was acquired at an average price of $4.62 per share, for a total transaction of $201,062.40. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Velan Capital, L.P. acquired 130,826 shares of the firm’s stock in a transaction on Friday, August 23rd. The stock was purchased at an average price of $4.31 per share, with a total value of $563,860.06. The disclosure for this purchase can be found here. Over the last ninety days, insiders acquired 677,306 shares of company stock worth $2,968,406. 4.26% of the stock is owned by corporate insiders.

NASDAQ:PGNX remained flat at $$5.54 during mid-day trading on Thursday. 278,694 shares of the company’s stock traded hands, compared to its average volume of 1,026,258. Progenics Pharmaceuticals, Inc. has a one year low of $3.42 and a one year high of $7.43. The company has a current ratio of 4.25, a quick ratio of 4.25 and a debt-to-equity ratio of 0.71. The company has a market capitalization of $457.16 million, a PE ratio of -8.79 and a beta of 2.78. The business’s 50-day moving average price is $4.59 and its two-hundred day moving average price is $4.77.

Progenics Pharmaceuticals (NASDAQ:PGNX) last posted its quarterly earnings results on Friday, August 9th. The biotechnology company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.02). Progenics Pharmaceuticals had a negative net margin of 339.86% and a negative return on equity of 65.17%. The business had revenue of $9.97 million during the quarter, compared to analysts’ expectations of $6.40 million. On average, equities research analysts predict that Progenics Pharmaceuticals, Inc. will post -1 EPS for the current fiscal year.

Progenics Pharmaceuticals Company Profile

Progenics Pharmaceuticals, Inc, an oncology company, develops, manufactures, and commercializes pharmaceutical products and other technologies to target, diagnose, and treat cancer cancer in the United States and internationally. The company's product candidates include Azedra, a radiotherapeutic product candidate for the treatment of iobenguane scan positive, unresectable, and locally advanced or metastatic pheochromocytoma or paraganglioma for adult and pediatric patients; PyL, a clinical-stage fluorinated prostate specific membrane antigen (PSMA)-targeted PET/CT imaging agent for prostate cancer; and 1095, a PSMA-targeted Iodine-131 labeled small molecule, which is in Phase II clinical trial for the treatment of metastatic castration-resistant prostate cancer.

Featured Story: Coverage Ratio

Want to see what other hedge funds are holding PGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX).

Institutional Ownership by Quarter for Progenics Pharmaceuticals (NASDAQ:PGNX)

Receive News & Ratings for Progenics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit